November 7, 2017 : DCMS #370

DISASTERS AVERTED — Near Miss Case Studies

Excessive Needle Bruising Conundrum

EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners

Aaron Vinik Part 1, INGAP Research

HOMERUN SLIDES — Great Clinical Presentation Highlights

Albuminuria: A Lot More Than Just a Little Protein in the Urine Part 12

CLINICAL GEMS — The Best from Diabetes Texts

International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #98: Metabolomics: Applications in Type 2 Diabetes Mellitus and Insulin Resistance Part 4

MOST POPULAR ARTICLES OF THE MONTH

#1 The Effects Of Dietary Carbohydrate Restriction On Glucose-Lowering Effect In T2DM
#2 Carbohydrate Timing Affects Glucose and Insulin Excursions
#3 Type 1 Cured in Mice

Our publisher got a chance to sit down with Dr Aaron Vinik at a recent AACE meeting. For those of you who have been following our publication for the past 18 years, you have seen Dr. Vinik’s name repeatedly. He was one of the first “legends in diabetes” to have faith in our fledgling publication. One of the first features we carried was the good doctor’s research with INGAP.

This week, he shared an update with Steve on INGAP and why the road to success is so hard. His information ties right into the fourth and final segment of this clinical text chapter on Metabolomics.

Dave Joffe

Editor-in-chief

A physician asked me to see his patient, a middle-aged woman who was using an insulin pen.  She had extensive bruising at her injection sites, with no simple explanation.  She was not taking any medications associated with increased bleeding, and did not bruise easily otherwise. The physician wondered if there was something else about her injection technique that produced the bruising.

In part 1 of this Exclusive Interview, Dr. Aaron Vinik talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the current progress of INGAP and the challenges yet to be overcome.

In this week’s Homerun Slides, we conclude our 12-part series with pharmacologic approaches to treating chronic kidney disease in type 2.

Future directions and potential application of metabolite profiling in type 2 diabetes: metabolomics approaches have unmasked a variety of metabolic pathways influenced by T2DM or insulin resistance, moving the field of metabolic physiology beyond a “glucocentric” viewpoint of these conditions. However, a difficulty in interpretation is that the fasting concentration of a metabolite only reflects a single moment in time, and etiology or tissue origins of any metabolite differences across comparator groups requires further validation.

Recent meta-analysis conducted to address ideal amount of dietary carbohydrates in the management of T2DM.

Meal sequencing may decrease glucose levels and insulin utilization.

Ralph DeFronzo and his researchers at UT Health at San Antonio announced that they have cured type 1 diabetes.